Prospective Multicenter Study of the Relationship Between Virological Effectiveness and Compliance in HIV-1-infected Patients Treated With Bictegravir

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-02-11

Study Completion Date

2027-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Modern once-daily antiretroviral therapies have evolved considerably, improving patients' quality of life. However, sub-optimal adherence to antiretroviral therapy (ART) can lead to insufficient viral suppression and the emergence of resistant HIV strains. In particular, several populations encountered in HIV clinical practice face obstacles to optimal adherence.

The investigators propose the prospective multicenter cohort study BICTECAPS, evaluating the effectiveness of the combination therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in routine practice. The investigators hypothesize that the pharmacokinetic profile and genetic barrier provided by B/F/TAF will enable a high rate of virological suppression at low to moderate levels of adherence, probably 100% virological suppression above 70% adherence.

The study is planned to include 120 patients with HIV infection treated with B/F/TAF, over a planned 2-year period with usual follow-up.

The aim of this work is to evaluate virological suppression rates at 6 and 12 months according to adherence levels defined by electronic antiretroviral monitoring caps (MEMS caps) and by intra-cellular TAF assay on blotting paper (dried blood spot, DBS).

The investigators hope to generate real-life data on B/F/TAF use from population groups generally under-represented in clinical trials, including robust measurements of adherence patterns using MEMS caps and DBS.

. Key words : HIV-1 ; B/F/TAF ; Adherence ; Forgiveness

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adherence to Dolutegravir and Outcome

NCT02878642

HIV

UNKNOWN

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

NCT04653194

Human Immunodeficiency Virus

COMPLETED PHASE3

Patient-Reported Outcomes HIV BItherapy

NCT04788784

HIV/AIDS and Infections Patient Preference

UNKNOWN

Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules

NCT00937729

HIV1 Infection HIV Infections

TERMINATED

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

NCT00102934

HIV Infections

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Title Etude multicentrique prospective de la relation entre efficacité virologique et observance chez des patients infectés par le VIH-1 traités par BICTEGRAVIR

Type or research Non interventional research (NIR)

Target population People living with HIV (PLWH)

Objectives Primary objective:

\- To explore the effectiveness of antiretroviral treatment with B/F/TAF by virological suppression rate (plasma HIV-RNA) at 6 months in real life according to adherence patterns defined by electronic antiretroviral monitoring caps (MEMS caps) and by intra-cellular TAF assay.

Secondary objective(s):

* To explore the effectiveness of antiretroviral treatment with B/F/TAF by the rate of virological suppression (plasma HIV-RNA) at 12 months in real life, according to adherence patterns defined by electronic antiretroviral monitoring caps (MEMS caps).
* Evaluate the risk of emergence of resistance mutations in cases of HIV RNA replication with B/F/TAF.
* Evaluate the safety profile of B/F/TAF in real-life practice.
* Evaluate the quality of life of participants treated with B/F/TAF in real-life practice.

Inclusion Criteria -

* Person living with HIV-1
* 18 years of age or older
* Having been informed about the study (non-opposition)
* Accepts the use of electronic antiretroviral monitoring caps (MEMS caps)
* Person treated or starting treatment with bictegravir/emtricitabine/tenofovir (B/F/TAF; antiretroviral treatment naïve, changing treatment, virological failure) Exclusion criteria -
* Pregnant women
* People living with HIV (PLHIV) unable to assume responsibility for treatment compliance (impaired judgment, guardianship, institutionalization)
* PLWH receiving assistance incompatible with the use of the electronic pillbox

Endpoints

Primary :

\- Virological failure at 6 months defined as a confirmed plasma viral load \>50 copies/mL or a single plasma viral load \>200 copies/mL (HIV RNA).

Secondary :

* Virological failure at 12 months as defined above
* Rate of side effects measured by CTCAE V.5
* Emergence of drug resistance mutations according to ANRS AC11 V35 in case of virological replication
* Quality of life measured by questionnaires

Procedure(s) or visit(s) added by research none

Nomber of patients 120 patients : Accuracy of at least +/-7% on virological failure rate

Number of centers 8 centers :

* CHU CAEN NORMANDIE
* CHU d'Orléans
* APHP Pitié-Salpêtrière
* CHU Poitiers
* CHU Nantes
* CHD La Roche sur Yon
* CH de Niort
* HCL Lyon

Project Milestone

* Expected start date of inclusions: 01/09/2024
* Inclusion duration: 2 years
* Duration of follow-up period: 12 months
* Planned end of study (issue of final report summary 1 year after last visit to last included subject): 01/09/2027

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Antiretroviral Therapy (ART) Adherence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults living with HIV-1 receiving or starting once-daily B/F/TAF-based antiretroviral therapy

Given our interest in covering a wide range of adherence profiles of B/F/TAF, the participation of PLHIV perceived by their physicians to be at risk of suboptimal adherence, such as a history of pre-existing resistance that does not affect B/F/TAF, immigrants/migrants, homeless/poorly housed, those with substance use disorders, transgender women, youth and those facing mental health issues, will be encouraged

Adherence measured by MEMS caps

Intervention Type DEVICE

The methodological choices made in this study are justified by the need to assess the effectiveness of bictegravir, taking into account the varying levels of adherence among PLHIV. The use of electronic antiretroviral caps (MEMS caps: https://aardexgroup.com/medication-event-monitoring-system/ ) and the intra-cellular TAF assay to measure drug concentrations will enable a combined, precise and objective assessment of treatment adherence, and constitute the originality of this research.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adherence measured by MEMS caps

The methodological choices made in this study are justified by the need to assess the effectiveness of bictegravir, taking into account the varying levels of adherence among PLHIV. The use of electronic antiretroviral caps (MEMS caps: https://aardexgroup.com/medication-event-monitoring-system/ ) and the intra-cellular TAF assay to measure drug concentrations will enable a combined, precise and objective assessment of treatment adherence, and constitute the originality of this research.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* People living with HIV-1
* Age greater than or equal to 18 years
* Having been informed about the study (non-opposition)
* Acceptance of the use of electronic antiretroviral monitoring caps (MEMS caps)
* People treated or starting treatment with bictegravir//emtricitabine/tenofovir (B/F/TAF; antiretroviral treatment naïve, changing treatment, virological failure)

Exclusion Criteria

* Pregnant women
* People living with HIV (PLHIV) living in institutionalization, with guardianship or impaired judgment (to avoid bias due to unability to assume responsibility for treatment compliance)
* PLHIV receiving assistance incompatible with the use of the electronic pillbox.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Laurent HOCQUELOUX, MD

Investigator coordinator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laurent HOCQUELOUX, M.D.

Role: PRINCIPAL_INVESTIGATOR

CHU d'Orléans (France)

Jean-Jacques PARIENTI, M.D., PhD

Role: STUDY_DIRECTOR

CHU de Caen (France)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Caen

Caen, , France

Site Status RECRUITING